NCT06934473 Effects of Endogenous GIP on Postprandial Blood Pressure in Healthy Individuals
| NCT ID | NCT06934473 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University Hospital, Gentofte, Copenhagen |
| Condition | Bloodpressure |
| Study Type | INTERVENTIONAL |
| Enrollment | 16 participants |
| Start Date | 2025-05-21 |
| Primary Completion | 2026-01-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 16 participants in total. It began in 2025-05-21 with a primary completion date of 2026-01-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The present study investigates the postprandial role of endogenous glucose-dependent insulinotropic polypeptide (GIP) on cardiovascular haemodynamics, hormone responses, and hypotensive symptoms during a tilt test.
Eligibility Criteria
Inclusion Criteria: 1. Age 18-40 years 2. BMI between 18.5 and 29.9 kg/m2 (both included) 3. Informed consent Exclusion Criteria: 1. Allergy or intolerance to ingredients included in the mixed meal 2. History of Orthostatic Hypotension (OH) or Postural Orthostatic Tachycardia Syndrome (POTS) or other autonomic dysfunction at the discretion of the investigators 3. Anaemia (haemoglobin below normal range \<7.3 mmol/L for women and \<8.3 mmol/L for men) 4. Kidney disease (estimated glomerular filtration rate (eGFR) \<90 ml/min/1.73 m2) at screening 5. Known liver disease and/or elevated plasma alanine aminotransferase (ALT) \> three times the upper limit of normal at screening 6. Treatment with antihypertensives 7. Treatment with GLP-1RA (Glucagon-like Peptide-1 Receptor Agonist) 8. Treatment with SNRI (Serotonin and Noradrenalin Reuptake Inhibitor) or treatment within two weeks before the first experimental day 9. Any ongoing medication that the investigator evaluates would interfere with trial participation 10. Any physical or psychological condition that the investigator evaluates would interfere with trial participation, including any acute or chronic illnesses 11. Any concomitant disease or treatment that, at the discretion of the investigators, might jeopardize the participant's safety during the trial 12. Alcohol/drug abuse as per discretion of the investigators 13. Pregnancy or breastfeeding 14. Participation in any other clinical trial during the study period 15. Mental incapacity or language barriers that preclude adequate understanding or cooperation or unwillingness to comply with trial requirements or pr discretion of the investigator
Frequently Asked Questions
Who can join the NCT06934473 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 40 Years, studying Bloodpressure. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06934473 currently recruiting?
Yes, NCT06934473 is actively recruiting participants. Visit ClinicalTrials.gov or contact University Hospital, Gentofte, Copenhagen to inquire about joining.
Where is the NCT06934473 trial being conducted?
This trial is being conducted at Copenhagen, Denmark, Copenhagen, Denmark.
Who is sponsoring the NCT06934473 clinical trial?
NCT06934473 is sponsored by University Hospital, Gentofte, Copenhagen. The trial plans to enroll 16 participants.